Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.